Company Profile

TriLink BioTechnologies Inc (AKA: TriLink)
Profile last edited on: 1/24/16      CAGE: 3Y9Z9      UEI: JTZNJ1K5HUA4

Business Identifier: Specialty Oligonucleotides and Nucleoside Triphosphates
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9955 Mesa Rim Road
San Diego, CA 92121
   (858) 546-0004
Location: Single
Congr. District: 52
County: San Diego

Public Profile

TriLink BioTechnologies, Inc. provides services for educators and academic researchers in gene therapy, nucleoside chemotherapy, oligonucleotide therapy, and diagnostics. It manufactures custom oligonucleotides, modified nucleoside triphosphates, and CleanAmp PCR products for research, diagnostic, therapeutic, and OEM markets; modified nucleic acid products, including phosphoramidites and other small molecules; and oligonucleotides, including custom synthesis and stocked oligonucleotides. The company also provides modified compounds, including aminoallyl, biotin, and two' fluoro nucleotides; specialty modified nucleotides, such as bisphosphates, a series of monophosphates, and CAP and mCAP; custom chemistry and contract research services, including the synthesis of unique phosphoramidites and polyphosphates, including mono-,di-and triphosphates, and other small molecules; and long RNA transcript synthesis and ISO/QSR compliant cGMP production facility services. In addition, it offers CleanAmp PCR kits, PCR reagents, dNTPs, GC-rich PCR, and primers and amidites. The company provides its products via online, email, and phone order. TriLink BioTechnologies, Inc. was founded in 1996 and is based in San Diego, California.|

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $132,803
Project Title: Improved Library Preparation Workflows For Next Generation Sequencing
2011 1 NIH $99,462
Project Title: Thermally Activatable Probes And Cofactors For Hot Start Ligase Chain Reaction
2011 2 NIH $816,800
Project Title: Chemical Determinants Of Dna Ligase Fidelity
2009 2 NIH $849,851
Project Title: Chemically Modified dNTPs as a General Approach for Improved Hot Start PCR
2007 2 NIH $847,201
Project Title: Reagents for Preparing Structure-Free DNA and RNA

Key People / Management

  Richard Hogrefe -- President

  Terry Beck -- Sr. Vice President

  Howard Gamper

  Alexandre Lebedev -- Senior Principal Sceintist

  Natasha Paul

  Chris Perez -- Director of Business Management

  Gerald Zon